David Geffen School of Medicine, University of California Los Angeles Comprehensive Epilepsy Program, VA Greater Los Angeles Healthcare System West Los Angeles, CA, USA.
Epilepsy Curr. 2007 May-Jun;7(3):61-7. doi: 10.1111/j.1535-7511.2007.00171.x.
One by one, mutation-containing mendelian genes that cause monogenic juvenile myoclonic epilepsies (JME) and single nucleotide polymorphisms (SNP)-susceptibility alleles that increase risks for nonmendelian complex JME should fall to the power of molecular genetics. Of 15 chromosome loci, 3 mendelian genes (alpha1-subunit of the GABA(A) receptor [GABRA1], chloride channel 2 gene [CLCN2], and Myoclonin1/EFHC1) and 2 SNP-susceptibility alleles of putative JME genes in epistases (bromodomain-containing protein 2 [BRD2] and connexin [Cx]-36) have been identified, so far. Antiepileptic drugs now can be designed against the specific molecular defects of JME.
一个接一个,引起单基因青少年肌阵挛性癫痫 (JME) 的突变孟德尔基因和增加非孟德尔复杂 JME 风险的单核苷酸多态性 (SNP)-易感等位基因应该被分子遗传学所攻克。在 15 个染色体位点中,已经确定了 3 个孟德尔基因(GABA(A)受体的 alpha1-亚基[GABRA1]、氯离子通道 2 基因[CLCN2]和肌阵挛蛋白 1/EFHC1)和 2 个假定的 JME 基因的 SNP-易感等位基因(溴结构域蛋白 2 [BRD2]和连接蛋白 [Cx]-36)处于上位性。到目前为止,已经可以针对 JME 的特定分子缺陷设计抗癫痫药物。